SanBio Co (JP:4592) has released an update.
SanBio Co., Ltd. has been granted a new patent in the US for its cell therapy product SB623, aimed at treating chronic ischemic stroke. This patent is a strategic move to bolster the company’s intellectual property portfolio and enhance its market presence, especially in the US. While the patent acquisition is significant, it is expected to have a minimal impact on the current fiscal year’s financial performance.
For further insights into JP:4592 stock, check out TipRanks’ Stock Analysis page.
